Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;9(4):476-481.
doi: 10.1158/2159-8290.CD-18-1357. Epub 2019 Mar 12.

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors

Patrick A Ott  1   2   3   4 , Catherine J Wu  5   6   7   8
Affiliations

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors

Patrick A Ott et al. Cancer Discov. 2019 Apr.

Abstract

Lack of tumor T-cell infiltration is a barrier to the efficacy of immune checkpoint inhibitors and other immunotherapies in patients with cancer. Because of their ability to activate and augment tumor-specific T cells, vaccines are an attractive approach to direct T-cell responses into the tumor.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest disclosures:

P.A.O has received research funding from and has advised Neon Therapeutics, BMS, Merck, CytomX, Pfizer, Novartis, Celldex, Amgen, AZ/MedImmune, Armo BioSciences, Array, and Roche/Genentech.

C.J.W. is a founder of Neon Therapeutics and member of its scientific advisory board. C.J.W. is subject to a conflict of interest management plan for the reported studies because of her competing financial interests in Neon Therapeutics. Under this plan, C.J.W. may not access identifiable human subjects data nor otherwise participate directly in the IRB-approved protocol reported herein. C.J.W.’s contributions to the overall program strategy and data analyses occurred on a de-identified basis.

Patent applications have been filed on aspects of the described work entitled as follows: Compositions and Methods for Personalized Neoplasia Vaccines (C.J.W.), Methods for Identifying Tumor Specific Neo-Antigens (C.J.W.), and Combination Therapy for Neoantigen Vaccine (C.J.W.).

Figures

Figure 1:
Figure 1:
Cancer vaccines can activate, amplify, and steer the immune response towards the generation of cancer-specific T cells (inset). As a result, vaccine-induced, tumor-antigen specific T cells are driven into the tumor.
See this image and copyright information in PMC

References

    1. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348(6230):62–8 doi 10.1126/science.aaa4967. - DOI - PMC - PubMed
    1. Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 2016;16(9):566–81 doi 10.1038/nrc.2016.97. - DOI - PMC - PubMed
    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348(6230):56–61 doi 10.1126/science.aaa8172. - DOI - PubMed
    1. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568–71 doi 10.1038/nature13954. - DOI - PMC - PubMed
    1. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017;127(8):2930–40 doi 10.1172/JCI91190. - DOI - PMC - PubMed

Publication types

Substances